Published in The Journal of endocrinology
Prostaglandins inhibit insulin secretion in a manner similar to that of norepinephrine (NE) and somatostatin. As NE inhibits endocytosis as well as exocytosis, we have now examined the modulation of endocytosis by prostaglandin E1 (PGE1). Endocytosis following exocytosis was recorded by whole-cell patch clamp capacitance measurements in INS-832/13 ...
Published in AAPS PharmSciTech
Lipo-PGE1 is the most widely used formulation of PGE1 in clinic. However, PGE1 is easier to leak out from lipo-PGE1 and this will lead to the phlebophlogosis when intravenous injection. The stability of lipo-PGE1 in storage and in vivo is also discounted. The aim of this study is to develop a long-circulating prostaglandin E1-loaded nanoemulsion mo...
Published in Medical devices (Auckland, N.Z.)
Treatment for persistent pulmonary hypertension of the newborn (PPHN) aims to reduce pulmonary vascular resistance while maintaining systemic vascular resistance. Selective pulmonary vasodilation may be achieved by targeting pulmonary-specific pathways or by delivering vasodilators directly to the lungs. Abrupt withdrawal of a pulmonary vasodilator...
Published in Journal of wound care
Lipo-prostaglandin E1 (lipo-PGE1) is a well-known potent vasodilator that increases peripheral blood flow. However, the effects of this agent on wound bed microcirculation still remain unclear. The present study aims to improve the experimental model which our group developed to visualise wound bed microcirculation and to evaluate acute stimulation...
Published in International journal of toxicology
Topical alprostadil cream (Vitaros) is approved in Canada and Europe for the treatment of erectile dysfunction. To determine the effects on the female urogenital tract with repeated administration of the entire dose (300 μg alprostadil containing 2.5% dodecyl-2-n,n-dimethylaminopropionate hydrochloride), the vaginal pH, flora, and histology were as...
Published in Clinical Biochemistry
•Prasugrel has superior platelet inhibition activity when compared to clopidogrel.•Clinically, there are better cardiovascular outcomes in prasugrel compared to clopidogrel patients.•This phenomenon explains the higher rates of bleeding, that are associated with this drug.
Published in JACC: Cardiovascular Interventions
ObjectivesThis study sought to determine pharmacodynamic effects during the transition from intravenous cangrelor to oral ticagrelor and from oral ticagrelor to intravenous cangrelor. MethodsPatients (n = 12) with stable coronary artery disease who were taking aspirin 81 mg daily were recruited. On study day 1, they received a bolus plus 2-h infusi...
Published in Thrombosis Research
IntroductionThe paradigm of activation induced platelet aggregation has recently been refuted under blood flow conditions with shear rates exceeding 20,000s-1. These lead to reversible rolling platelet aggregates, which were dependent on the presence of immobilized and soluble von Willebrand factor. Material and MethodsIn vitro experiments using di...
Published in Journal of paediatrics and child health
Clinical diagnosis of DDCHD outside of a cardiac centre is challenging. No single factor predicts DDCHD. Combined interpretation of clinical, physiological and x-ray findings may assist.
Published in The Journal of Thoracic and Cardiovascular Surgery
ObjectiveThere is cross-center variability with regard to timing repair of non–ductal-dependent tetralogy of Fallot (TOF). We hypothesized that earlier repair in the neonatal period is associated with increased mortality and morbidity. MethodsThis was a retrospective analysis of the Pediatric Health Information System of tetralogy of Fallot patient...
